jama ophthalmology semaglutide - Most viewed this week from JAMA Ophthalmology: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic anterior ischemic optic neuropathy (NAION). https://ja.ma/4mO3NOU blindness and tirzepatide A small

It functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist

To understand the durability and stability of weight outcomes after stopping GLP-1s, we studied 188,722 patients who stopped using a GLP-1 medication after being on it for at least 90 days and who lost at least 5 pounds while on it

No alcohol, tobacco, chronic fast-food intake, or recent acute illness (such as fever or infections) was reported

Autoimmune-related back conditions might improve with regular protocols

Eur J Clin Pharmacol 59:243251 van Lingen RA, Deinum J, Quak J, Kuizenga A, van Dam JG, Anand K et al (1999) Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates

Scenario 3: Regulatory challenge or legislative change